

Expression of *erbB-1* and *erbB-2* genes in normal and pathological human endometrium

MAGDALENA BRYŚ¹, ANDRZEJ SEMCZUK², TOMASZ RECHBERGER² and WANDA M. KRAJEWSKA¹

¹Department of Cytobiochemistry, University of Lodz, Lodz;

²Second Department of Gynecology, Lublin University School of Medicine, Lublin, Poland

Received January 9, 2007; Accepted March 19, 2007

Abstract. Overexpression of the *erbB-1* (EGFR, epidermal growth factor receptor) and *erbB-2* (HER2/neu) proteins contributes to the aggressive behavior of malignant tumors originating from the endometrium. We currently examined whether the trend of these proteins to overexpression is a direct effect of their gene transcriptional activities. Expression of the *erbB-1/erbB-2* genes was measured applying the quantitative RT-PCR technique in 25 uterine carcinomas, 12 normal endometria, a carcinosarcoma and a case of botryoid sarcoma of the uterine cervix. We showed that *erbB-1* mRNA was overexpressed in 48% (12/25) and *erbB-2* mRNA was overexpressed in 8% (2/25) of the analysed tumors. The level of expression appeared to be significantly higher in the malignant tumors as compared to the benign ones for *erbB-1* and for *erbB-2* ($p=0.0001$ and $p=0.008$, respectively). A significant correlation between *erbB-1* overexpression and tumor differentiation was found (Spearman rank correlation test, $p<0.001$). Concomitant *erbB-1* and *erbB-2* overexpression was detected only in 1 out of 25 (4%) uterine neoplasms. *erbB-1* was overexpressed in a sarcoma botryoides of the uterine cervix. Our data suggest that *erbB-1/erbB-2* overexpression is a direct effect of higher than normal transcriptional activity of the encoding genes in a subset of human endometrial carcinomas.

Introduction

Endometrial cancer is one of the most common female genital tract malignancies in the Western world (1). In the United States, 40,230 new cases and 7,090 deaths were anticipated in

2004, making it the 4th most common cancer in women (2). The incidence of endometrial cancer has also increased in Poland during the last three decades, and 3,796 new cases were diagnosed in 2002 (3). Many risk factors are involved in the etiology of endometrial malignancy, including obesity, late menopause, anovulatory cycles, hypertension, diabetes mellitus and unopposed estrogenic stimulation (4). Family history may also be a risk factor as familial clustering of endometrial cancers has been reported (5). Sandles and co-investigators (5) suggested that two 'genetic models' may be implicated in the development of endometrial adenocarcinoma: the cancer family syndrome (Lynch II or hereditary nonpolyposis colorectal cancer syndrome) and a predisposition for endometrial adenocarcinoma alone.

Several studies have demonstrated the importance of epidermal growth factor (EGF)-related peptides and their receptors (*erbB-2/HER-2*, *erbB-3/HER-3* and *erbB-4/HER-4*), on the background of sex steroid effects, in normal, hyperplastic and neoplastic human endometrium (6,7). EGF-related growth factors play a regulatory role, particularly influencing the mitogenic activity of human endometrial adenocarcinoma cell lines in serum-free medium (8,9). The phosphatidylinositol cascade appears to be an important signal transduction pathway in cell culture, mediating the growth effects of EGF on endometrial cancer cell line HEC-1-A (10). In the poorly-differentiated endometrial cancer cell line KLE, EGF stimulation of cell growth is exerted through both protein kinase C-dependent and -independent manners (11).

EGFR, HER-2 and EGF or TGF α can be detected in various epithelial tumors originating from the female genital tract (12-16). Expression of mRNA for EGF, HB-EGF and TGF α has been detected in normal human endometrium (15). In endometrial cancer, the same authors detected EGF, HB-EGF and TGF α mRNA expression in 76.5, 66.7 and 68.4% of cases, respectively (15).

Previously, *erbB-2* protein overexpression was associated with impaired overall survival of patients affected by endometrial cancer (17,18). To note, uterine papillary serous carcinomas (UPSC), notorious for their aggressive behavior and unfavorable prognosis, revealed *erbB-2* overexpression in 80% of cases (19).

However, one can speculate that *erbB-1* and *erbB-2* protein overexpression results from the differential expression pattern of related genes during endometrial tumorigenesis.

Correspondence to: Professor Magdalena Bryś, Department of Cytobiochemistry, University of Lodz, Banacha Str. 12/16, Lodz 90-237, Poland

E-mail: zreg@biol.uni.lodz.pl

Abbreviations: EGFR, epidermal growth factor receptor; HB-EGF, heparin-binding epidermal growth factor; TGF α , transforming growth factor α ; SD, standard deviation

Key words: *erbB-1*, *erbB-2*, RT-PCR, endometrial cancer

Therefore, the current study was aimed at investigating *erbB-1* and *erbB-2* gene expression in normal and pathological human endometrium. Moreover, the correlation between gene expression and various clinicopathological variables of cancer was also studied. Uterine carcinosarcoma and a botryoid sarcoma of the uterine cervix were also included.

Materials and methods

Patients and material. The studied material comprised endometrial carcinomas from 25 patients who received surgical management at the Second Department of Gynecology, Lublin University School of Medicine, Lublin, Poland between 2003 and 2005. The mean patient age was 61 years (range, 50-80). None of the subjects had received hormonal therapy, radiation therapy or chemotherapy before surgery. As a control, 12 normal endometrial tissues (2 from the proliferative and 2 from the secretory phase of the menstrual cycle, as well as 8 atrophic endometria) were collected from women who underwent surgery unrelated to endometrial pathology (uterine leiomyomas, early-stage cervical cancer or ovarian cysts). Uterine carcinosarcoma and a case of botryoid sarcoma of the uterine cervix (rhabdomyosarcoma embryonale) were also included in the study.

The clinicopathological features of the endometrial cancer patients are summarized in Table I. Briefly, gross examination revealed that 20 of the 25 (80%) tumors were of stage I according to FIGO classification (20), and most (19 out of 25, 76%) were of the endometrioid type at presentation (21).

The Independent Ethics Committee of the Lublin University School of Medicine, Lublin, Poland, approved the experiments, and informed written consent was obtained from all subjects.

At surgery, after the uterus had been removed and cut, a portion of the tissue was immediately fixed in buffered formalin (pH 7.4) for routine pathological assessment. The remaining portion was immediately scraped into a sterile eppendorf tube, frozen in liquid nitrogen and stored in a deep-freezer (-80°C) until assayed. During this procedure, the tissue obtained from the uterine cavity was not cross-contaminated by the material from the cervical canal.

RNA extraction and RT-PCR. Total RNA was isolated according to the method of Chomczynski and Sacchi (22) and quantified spectrophotometrically at 260 nm. High quality RNA was defined by a ratio 260 nm/280 nm of 1.8-2.0. RT-PCR was performed applying the RNA PCR kit, version 2.1 (Takara Shuzo Co., Ltd., Kyoto, Japan) according to the manufacturer's instructions.

erbB-1, *erbB-2* and *glyceraldehyde phosphate dehydrogenase (GAPDH)* as a control, were independently amplified according to Thøgersen and co-workers (23). The specific primer sequences are shown in Table II. PCR products were separated on 1.5% TBE-agarose gel at 100 V for 30 min and visualised with ethidium bromide staining. For qualitative and quantitative analysis of ethidium bromide-stained gels, a video densitometer (Biotec-Fischer, Germany) and software Gel-Pro® analyzer 3.0 (Media Cybernetics, USA) were applied.

Table I. Clinicopathological variables of endometrial cancer patients.

Variable	Number	Percent (%)
Age of patients (years)		
<60	11	44
≥60	14	56
Surgical stage		
I	20	80
II	1	4
III	2	8
IV	2	8
Histologic type		
Endometrioid adenocarcinoma	19	76
Adenosquamous carcinoma	5	20
Clear-cell carcinoma	1	4
Histologic grade		
G1	7	28
G2	11	44
G3	7	28
Myometrial invasion		
<1/2	12	48
>1/2	13	52
Coexistence of hyperplastic and neoplastic endometrium		
yes	5	20
no	20	80
Lymph node metastasis		
yes	4	16
no	14	56
n. e.	7	28

n.e., not evaluated.

The ratio between the PCR-amplified gene and its amplified control was obtained for each analysed sample. In the PCR reactions, all ratios were normalised to the appropriate control ratio. All PCR and RT-PCR reactions were repeated 3 times for each sample, and the ratios were separately quantified.

To exclude contamination of genomic DNA as a source for amplified products, each reaction was also carried out without reverse transcriptase.

The integrated optical density (IOD) of the bands, in a digitalised picture, was separately measured as described previously (24). The relative expression of the *erbB-1* or *erbB-2* genes was determined as the IOD ratio of the analysed gene over the IOD of *GAPDH*. Overexpression of the gene was revealed when *erbB-1/GAPDH* and *erbB-2/GAPDH* IOD ratios were higher than 1.2 and 1.33, respectively (above the mean IOD value for the control group + 3 SD values).

Statistical analysis. None of the parameters recorded in the tumor material passed tests for being normally distributed

Gene	Primer	Base pairs (bp)
<i>erbB-1</i>	Upstream	5'-GACCCTCCGGGACGG-3'
	Downstream	5'-GGCATAGGAATTTTCGTAGTACATAT-3'
<i>erbB-2</i>	Upstream	5'-AACTGCACCCACTCCTGTGT-3'
	Downstream	5'-CAGGGATCCAGATGCCCTTG-3'
<i>GAPDH</i>	Upstream	5'-GCCACATCGCTCAGACACCA-3'
	Downstream	5'-GATGACCCTTTTGGCTCCCC-3'




Figure 1. Analysis of *erbB-1* (A) and *erbB-2* (B) mRNA expression in normal (lane 1) and endometrial cancer tissues (lanes 2-6) with *GAPDH* mRNA (C) as a reference gene. M, molecular weight marker (PCR marker, 50-2,000 bp; Sigma-Aldrich, USA).

(Smirnow-Kolmogorov test) and the non-parametrical statistical tests (Mann-Whitney U test, the Fisher exact test or the Spearman rank correlation test) were applied. The data were statistically analysed using STATISTICA for Windows, version 5.1 (Statsoft, Tulsa, OK, USA). $p \leq 0.05$ was considered statistically significant.

Results

Expression of *erbB-1* and *erbB-2* was studied by quantitative RT-PCR analysis with *GAPDH* applied as a reference gene (Fig. 1). There were 12 normal endometrial tissues, and the mean \pm SD of the *erbB-1/GAPDH* and *erbB-2/GAPDH* IOD ratios were 0.96 ± 0.08 (range, 0.85-1.08) and 1.12 ± 0.07 (range, 0.97-1.26), respectively. For tumor samples, analogous IOD ratios (mean \pm SD) were calculated as

1.20 ± 0.06 (range, 1.11-1.36) and 1.21 ± 0.09 (range, 0.99-1.38) for *erbB-1* and *erbB-2*, respectively. In both cases, the level of expression appeared to be higher in the malignant cases as compared to the benign ones ($p=0.0001$ and $p=0.008$, respectively).

erbB-1 overexpression was reported in 48% (12/25) of the endometrial carcinomas. A significant correlation between *erbB-1* overexpression and tumor differentiation was found (Spearman rank correlation test, $p < 0.001$). There was no correlation between *erbB-1* overexpression and patient age, clinical stage, histological type, depth of myometrial invasion, lymph node metastasis or coexistence of hyperplastic and neoplastic human endometrium.

erbB-2 overexpression was observed in 2 out of 25 (8%) of the uterine malignant tumors. All overexpressed cases were well-differentiated endometrioid-type endometrial carcinomas, stage Ic with deep myometrial infiltration. Concomitant *erbB-1* and *erbB-2* overexpression was detected only in 1 out of 25 (4%) neoplasms.

erbB-1/GAPDH and *erbB-2/GAPDH* IOD ratios for carcinosarcoma were 1.02 and 1.11, respectively, whereas *erbB-1* was overexpressed in a sarcoma botryoides of the uterine cervix (*erbB-1/GAPDH* IOD ratio, 1.24). The *erbB-2/GAPDH* IOD ratio for rhabdomyosarcoma embryonale was 1.2.

Discussion

Proto-oncogenes are a group of normal genes that play important roles in the regulation of cell proliferation. Abnormalities in the expression, structure, or activities of proto-oncogene products contribute to the development and maintenance of the cell malignant phenotype. The human *erbB-2* gene product, like the epidermal growth factor receptor, is a transmembrane receptor protein that plays an important role in coordinating the complex erbB signaling network that is responsible for regulating cell growth and differentiation (25,26).

Several studies have focused on the expression of *erbB-1* and/or *erbB-2* and their biological or clinical involvement in endometrial tumorigenesis (27-31).

In 65 endometrial carcinomas, 71% showed *erbB-1* immunoreactivity but also 77% of atrophic endometria and 54% of endometrial adenomatous hyperplasia were positive (28). *ErbB-1* immunoreactivity seems to be related to the endometrial cancer histotype, regardless of the tumor grade or extent of myometrial infiltration (29). Additionally, strong

(3+) or diffuse (2+ or 1+) immunostaining for *erbB-1* was found in 21/128 (32%) and 83/128 (65%) of endometrial carcinomas, respectively. However, protein expression did not correlate with any known prognostic variables, whereas expression of *erbB-2* was reported to correlate with tumor type ($p=0.046$), especially with clear-cell carcinomas of the endometrium (30). On the contrary, however, *erbB-1* expression was correlated with histological grade ($p=0.004$) and patient age ($p=0.04$) in human endometrioid-type endometrial carcinomas (31).

Our results indicated that the *erbB-1* and *erbB-2* mRNA expression level was significantly higher in malignant human endometria compared to benign ones. Moreover, a significant correlation between *erbB-1* overexpression and tumor differentiation was also observed ($p<0.001$). Previously, Pfeiffer and co-workers (15) reported higher mRNA levels of all EGF receptors in human endometrial carcinomas than in normal endometrial controls. However, this increase was only significant for TGF α and amphiregulin ($p<0.005$). This allows us to speculate that *erbB-1/erbB-2* overexpression is a direct effect of higher than normal transcriptional activity of the encoding genes in a subset of human endometrial carcinomas.

It is worth pointing out that *erbB-1* and *erbB-2* expression may be a useful prognostic factor in endometrial carcinomas (17,18,31-34). *erbB-1*-positive endometrial carcinoma patients had a statistically shorter length of survival compared with those with *erbB-1*-negative tumors ($p=0.018$), but protein status failed to retain prognostic value applying multivariate analysis (31). Moreover, *erbB-1* expression was significantly correlated with decreased patient survival not only for endometrioid-type endometrial adenocarcinomas, but also for the serous papillary and clear cell categories (32). Previously, Hetzel *et al* (17) reported that strong *erbB-2* immunostaining in endometrial cancer was an independent prognostic variable applying univariate and multivariate analysis (213 out of 247 tumors were at I-II stages of the disease). Kohlberger and co-investigators (18) showed that *erbB-2* oncoprotein expression was significantly correlated with impaired overall patient survival ($p=0.04$). *erbB-2* expression, instead of vascular invasion-associated changes and tumor aneuploidy, was found to independently correlate with survival in FIGO stage I endometrioid endometrial carcinomas (33). In a previous study, p53 overexpression predicted the recurrence of endometrial cancer better than HER-2/neu immunostaining, although simultaneous protein overexpression indicated a worse patient outcome (34). However, there are additional reports which fail to confirm these observations (35,36).

The current results seem to be of great importance when referring to the data concerning *erbB-1* and *erbB-2* protein levels in human malignancies. The relative mitogenic and transforming abilities of *erbB* proteins and their ligands suggest that cells co-expressing *erbB-1/erbB-2* are more effectively transformed than cells expressing *erbB-1* alone (37). The observation that *erbB-2* can transpotentiate the proliferative effect of epidermal growth factor more than *erbB-3* is interpreted in terms of heterodimer formation, particularly because *erbB-1/erbB-2* interactions are more prevalent than *erbB-1/erbB-3* (38). Currently, concomitant *erbB-1/erbB-2* mRNA overexpression was found only in 4%

of endometrial carcinomas. Further investigations on a large group of cases should clarify the influence of *erbB-1/erbB-2* overexpression on the clinical behavior of human endometrial carcinomas.

Finally, *erbB-1* was overexpressed (*erbB-1/GAPDH* IOD ratio, 1.24) in a case of a highly malignant tumor of the uterine cervix, botryoid sarcoma. Due to its rarity, instead of *TP53* deregulation as reported previously (39), *erbB-1* alterations may also have participated in the development and progression of this uncommon human neoplasm originating from the uterine cervix.

Attempts to elucidate the mechanisms of signal transduction via receptors of the *erbB* family, and especially the sequence of events which occurs during neoplastic transformation, seem to be enormously important from the therapeutic point of view, and lead to the more selective and effective use of inhibitors or antagonists of some transmitters (40). For example, the efficacy of herceptin therapy and the assessment of HER-2/neu have been proposed for chemotherapy-resistant, advanced-stage UPSC (41). The clinical utility of HER-2/neu or EGFR-targeted therapies in biphasic, highly aggressive neoplasms originating from the endometrium (carcinosarcoma) was also suggested (42).

Acknowledgements

The authors would like to acknowledge the staff at the Department of Pathology, Lublin University School of Medicine, Lublin, Poland especially Professor E. Korobowicz, Head of the Department, for classifying the samples according to the WHO staging system. This study was supported by grant no. 505/429 from the University of Lodz, Lodz, Poland.

References

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. *Lancet* 366: 491-505, 2005.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ and American Cancer Society: Cancer Statistics, 2004. *CA Cancer J Clin* 54: 8-29, 2004.
3. Wojciechowska U, Didkowska J, Tarkowski W and Zatonski W: Cancer in Poland in 2002. The Maria Skłodowska-Curie Memorial Cancer Center, National Cancer Registry, Warsaw, Poland, 2004.
4. Hacker NF: Uterine cancer. In: Practical Gynecologic Oncology. Berek JS and Hacker NF (eds). Lippincott Williams and Wilkins, Philadelphia, pp397-442, 2005.
5. Sandles LG, Shulman LP, Elias S, Photopoulos GJ, Smiley LM, Posten WM and Simpson JL: Endometrial adenocarcinoma: genetic analysis suggesting heritable site-specific uterine cancer. *Gynecol Oncol* 47: 167-171, 1992.
6. Hom YK, Young P, Wiesen JF, Miettinen PJ, Derynck R, Werb Z and Cunha GR: Uterine and vaginal organ growth requires epidermal growth factor receptor signaling from stroma. *Endocrinology* 139: 913-921, 1998.
7. Rasty G, Murray R, Lu L, Kubilis P, Benrubi G and Masood S: Expression of HER-2/neu oncogene in normal, hyperplastic, and malignant endometrium. *Ann Clin Lab Sci* 28: 138-143, 1998.
8. Pearl ML, Talavera F, Gretz HF III, Roberts JA and Menon KM: Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC-1-A and KLE. *Gynecol Oncol* 49: 325-332, 1993.
9. Lelle RJ, Talavera F, Gretz H, Roberts JA and Menon KM: Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. *Cancer* 72: 519-525, 1993.
10. Connor P, Talavera F, Kang JS, Burke J, Roberts J and Menon KM: Epidermal growth factor activates protein kinase C in the human endometrial cancer cell line HEC-1-A. *Gynecol Oncol* 67: 46-50, 1997.



IF III, Talavera F, Connor P, Pearl M, Lelle RJ, Roberts JA
Senon KM: Protein kinase C-dependent and -independent

- pathways mediate epidermal growth factor (EGF) effects in human endometrial adenocarcinoma cell line KLE. *Gynecol Oncol* 53: 228-233, 1994.
12. Gullick WJ, Marsden JJ, Whittle N, Ward B, Bobrow L and Waterfield MD: Expression of epidermal growth factor receptors on human cervical, ovarian and vulvar carcinomas. *Cancer Res* 46: 285-292, 1986.
 13. Bauknecht T, Kohler M, Janz I and Pfeiderer A: The occurrence of epidermal growth factor receptors and the characterisation of EGF-like factors in human ovarian, endometrial, cervical and breast cancer. EGF receptors and factors in gynecological carcinomas. *J Cancer Res Clin Oncol* 115: 193-199, 1989.
 14. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL and Bast RC Jr: Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. *Obstet Gynecol* 76: 381-387, 1990.
 15. Pfeiffer D, Spranger J, Al-Deiri M, Kimmig R, Fisseler-Eckhoff A, Scheidel P, Schatz H, Jensen A and Pfeiffer A: mRNA expression of ligands of the epidermal-growth-factor-receptor in the uterus. *Int J Cancer* 72: 581-586, 1997.
 16. Miturski R, Semczuk A, Postawski K and Jakowicki JA: Epidermal growth factor receptor immunostaining and epidermal growth factor receptor-tyrosine kinase activity in proliferative and neoplastic human endometrium. *Tumor Biol* 21: 358-366, 2000.
 17. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS and Podratz KC: HER-2/neu expression: a major prognostic factor in endometrial cancer. *Gynecol Oncol* 47: 179-185, 1992.
 18. Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz CH and Gitsch G: Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. *Cancer Lett* 98: 151-155, 1996.
 19. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ and Parham GP: Overexpression of HER-2/neu in uterine serous papillary cancer. *Clin Cancer Res* 8: 1271-1279, 2002.
 20. Mikuta JJ: Preoperative evaluation and staging of endometrial cancer. *Cancer* 76 (suppl 10): 2041-2043, 1995.
 21. Tavassoli FA and Devilee P: Pathology and genetics of tumours of the breast and female genital organs. International Agency for Research on Cancer (IARC), IARC Press, Lyon, 2003.
 22. Chomczynski P and Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate phenol-chloroform extraction. *Anal Biochem* 162: 156-159, 1987.
 23. Thøgersen VB, Bross P, Gregersen N and Nexø E: Quantitative analysis of the human epidermal growth factor receptor messenger RNA using reverse transcription-PCR: a methodological study of imprecision. *Clin Chem* 44: 1344-1346, 1998.
 24. Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Jakowicki JA and Krajewska WM: Expression and intracellular localization of Smad proteins in human endometrial cancer. *Oncol Rep* 10: 1539-1544, 2003.
 25. Graus-Porta D, Beerli RR, Daly JM and Hyner NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. *EMBO J* 16: 1647-1655, 1997.
 26. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. *Clin Cancer Res* 12: 5268-5272, 2006.
 27. Brumm C, Riviere A, Wilckens C and Loning T: Immunohistochemical investigation and Northern blot analysis of c-erbB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. *Virchows Arch A Pathol Anat Histopathol* 417: 477-484, 1990.
 28. Nyholm HC, Nielsen AL and Ottesen B: Expression of epidermal growth factor receptors in human endometrial carcinoma. *Int J Gynecol Pathol* 12: 241-245, 1993.
 29. Jasonni VM, Amadori A, Santini D, Ceccarelli C, Naldi S and Flamigni C: Epidermal growth factor receptor (EGF-R) and transforming growth factor alpha (TGFA) expression in different endometrial cancers. *Anticancer Res* 15: 1327-1332, 1995.
 30. Reinartz JJ, George E, Lindgren BR and Niehans GA: Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. *Hum Pathol* 25: 1075-1083, 1994.
 31. Niikura H, Sasano H, Matsunaga G, Watanabe K, Ito K, Sato S and Yajima A: Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. *Hum Pathol* 26: 892-896, 1995.
 32. Khalifa MA, Mannel RS, Haraway SD, Walker J and Min K-W: Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. *Gynecol Oncol* 53: 84-92, 1994.
 33. Nazeer T, Ballouk F, Malfetano JH, Figge H and Ambros RA: Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. *Am J Obstet Gynecol* 173: 1829-1834, 1995.
 34. Coronado PJ, Vidart JA, Lopez-Asenjo JA, Fasero M, Furio-Bacete V, Magrina J and Escudero M: P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. *Eur J Obstet Gynecol Reprod Biol* 98: 103-108, 2001.
 35. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD and Karlan BY: HER-2/neu, p53 and DNA analyses as prognosticators for survival in endometrial carcinoma. *Obstet Gynecol* 85: 729-734, 1995.
 36. Backe J, Gassel AM, Krebs S, Muller T and Caffier H: Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma. *Arch Gynecol Obstet* 259: 189-195, 1997.
 37. Kokai Y, Myers JN, Wada T, Brown VI, LeVeae CM, Davis JG, Dobashi K and Green MI: Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. *Cell* 58: 287-292, 1989.
 38. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation/neuregulin and epidermal growth factor. *Mol Cell Biol* 16: 5276-5287, 1996.
 39. Semczuk A, Baranowski W, Berbec H, Marzec B, Skomra D and Miturski R: Analysis of p53 and K-ras genes and their proteins in a sarcoma botryoides of the uterine cervix. *Eur J Gynaecol Oncol* 20: 311-314, 1999.
 40. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. *Nat Rev Cancer* 5: 341-354, 2005.
 41. Santin AD: HER2/neu overexpression: Has the Achilles' heel of uterine serous papillary carcinoma been exposed? *Gynecol Oncol* 88: 263-265, 2003.
 42. Livasy CA, Reading FC, Moore DT, Boggess JF and Lininger RA: EGFR expression and HER2/neu overexpression/ amplification in endometrial carcinosarcoma. *Gynecol Oncol* 100: 101-106, 2006.